Design, Synthesis, and Biological Evaluation of Novel Trifluoromethoxy Substituted Pyrazolines as Potential Tubulin Assembling Inhibitors

Abstract:

Breast cancer is a major health problem with an increasing number of cases over the years. Few classes of anticancer agents have been developed but they established toxic effects on normal cells. Despite the availability of many effective drugs to treat different types of cancers, chemotherapeutic drugs are unable to distinguish between healthy and cancerous cells, resulting in the risk of side effects and drugs resistance. There is a continuous effort to find new agents to help bring this disease under control. In this study, novel fluorinated pyrazolines derivatives (2a-c) were designed and synthesized via cyclo-condensation reaction of commercially available trifluoromethoxy phenylhydrazine with a series of chalcone derivatives (1a-c). These pyrazoline compounds, 2a-c exhibited inhibitory activity against MCF-7 cell lines with the IC₅₀ values of 7.62 ± 0.69, 29.61 ±1.60 and 14.38 ± 0.69 μM, respectively. These values are comparable to the positive control, Doxorubicin (IC₅₀ of 17.44 ± 5.32 μM). Pyrazoline 2a exhibited the best free binding energy of-10.8 kcal/mol compared to pyrazoline 2b and 2c which showed the free binding energy of-8.6 and-9.5 kcal/mol, respectively. Molecular docking results of pyrazoline 2a exhibited good interaction between OCF₃ moiety with EGFR active site, forming three π bonds which enhanced the anticancer activity. Therefore, pyrazoline 2a would provide promising access to future studies as a potential antitumor agent. Keywords: Fluorinated compounds, trifluoromethoxy, pyrazoline derivatives, molecular modelling, anticancer activity

• Periodical: Materials Science Forum (Volume 1061)
• Pages: 195-201
• DOI: https://doi.org/10.4028/p-e38749
• Online since: May 2022
• Authors: Maadh Jumaah, Melati Khairuddean*, Tutik Dwi Wahyuningsih
• Keywords: Anticancer Activity, Fluorinated Compounds, Molecular Modelling, Pyrazoline Derivatives, Trifluoromethoxy

References

[1] F. Giornal, S. Pazenok, L. Rodefeld, N. Lui, J.P. Vors, F.R. Leroux, Synthesis of diversely fluorinated pyrazoles as novel active agrochemical ingredients, J. Fluorine Chem. 152 (2013) 2–11.

DOI: 10.1016/j.jfluchem.2012.11.008

[2] R. Román, A. Navarro, D. Wodka, M. Alvim-Gaston, S. Husain, N. Franklin, A. Simón-Fuentes, S. Fustero, Synthesis of fluorinated and nonfluorinated tebufenpyrad analogues for the study of anti-angiogenesis MOA, Org. Process Res. Dev. 18 (2014) 1027–1036.

DOI: 10.1021/op500114v

[3] Q.W. Zhang, J.F. Hartwig, Synthesis of heteroaromatic trifluoromethyl ethers with trifluoromethyl triflate as the source of the trifluoromethoxy group, Chem. Commun. 54 (2018) 10124–10127.

DOI: 10.1039/c8cc05084h

[4] E. Schmitt, S. Bouvet, B. Pégot, A. Panossian, J.P, Vors, S. Pazenok, E. Magnier, F.R. Leroux, Fluoroalkyl amino reagents for the introduction of the fluoro(trifluoromethoxy)methyl group onto arenes and heterocycles, Org. Lett. 19 (2017) 4960–4963.

DOI: 10.1021/acs.orglett.7b02444

[5] J.C. Sloop, C. Holder, M. Henary, Selective incorporation of fluorine in pyrazoles, Eur. J. Org. Chem. 2015 (2015) 3405–3422.

DOI: 10.1002/ejoc.201500258

[6] E. Schmitt, A. Panossian, J.P. Vors, C. Funke, N. Lui, S. Pazenok, F.R. Leroux, A major advance in the synthesis of fluoroalkyl pyrazoles: Tuneable regioselectivity and broad substitution patterns, Chem. - Eur. J. 22 (2016) 11239–11244.

DOI: 10.1002/chem.201601621

[7] M. Abdel-Halim, B. Diesel, A.K. Kiemer, A.H. Abadi, R.W. Hartmann, M. Engel, Discovery and optimization of 1,3,5-trisubstituted pyrazolines as potent and highly selective allosteric inhibitors of protein kinase C-ζ, J. Med. Chem. 57 (2014) 6513–6530.

DOI: 10.1021/jm500521n

[8] P. Ahmad, H. Woo, K.Y. Jun, A.A. Kadi, H.A. Abdel-Aziz, Y. Kwon, A.M. Rahman, Design, synthesis, topoisomerase I & II inhibitory activity, antiproliferative activity, and structure–activity relationship study of pyrazoline derivatives: An ATP-competitive human topoisomerase IIα catalytic inhibitor, Bioorg. Med. Chem. 24 (2016) 1898–(1908).

DOI: 10.1016/j.bmc.2016.03.017

[9] Y.J. Qin, Y.J. Li, A.Q. Jiang, M.R. Yang, Q.Z. Zhu, H. Dong, H.L. Zhu, Design, synthesis and biological evaluation of novel pyrazoline-containing derivatives as potential tubulin assembling inhibitors, Eur. J. Med. Chem. 94 (2015) 447–457.

DOI: 10.1016/j.ejmech.2015.02.058

[10] T. Mosmann, Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays, J. Immunol. Methods 65 (1983) 55e63.

DOI: 10.1016/0022-1759(83)90303-4

[11] J.J. Liu, H. Zhang, J. Sun, Z.C. Wang, Y.S. Yang, D. Li, F. Zhang, H.B. Gong, H.L. Zhu, Synthesis, biological evaluation of novel 4, 5-dihydro-2H-pyrazole 2-hydroxyphenyl derivatives as BRAF inhibitors, Bioorg. Med. Chem. 20 (2012) 6089–6096.

DOI: 10.1016/j.bmc.2012.08.020

[12] E.C. McLoughlin, N.M. O'Boyle, Colchicine-binding site inhibitors from chemistry to clinic: A review, Pharmaceuticals 13 (2020) 8.

DOI: 10.3390/ph13010008

[13] Y. Lu, J. Chen, M. Xio, W. Li, D.D. Miller, An overview of tubulin inhibitors that interact with the colchicine binding site, Pharm. Res. 29 (2012) 2943–2971.

DOI: 10.1007/s11095-012-0828-z

[14] M. Dong, F. Liu, H. Zhou, S. Zhai, B. Yan, Novel natural product-and privileged scaffold-based tubulin inhibitors targeting the colchicine binding site, Molecules 21 (2016) 1375.

DOI: 10.3390/molecules21101375

[15] C.A. Lipinski, F. Lombardo, B.W. Dominy, P.J. Freeney, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Adv. Drug Delivery Rev. 23 (1997) 3–25.

DOI: 10.1016/s0169-409x(96)00423-1

[16] D. Ramírez, J. Caballero, Is it reliable to take the molecular docking top scoring position as the best solution without considering available structural data?, Molecules 23 (2018) 1038.

DOI: 10.3390/molecules23051038

[17] P.H.M. Torres, A.C.R. Sodero, P. Jofily, F.P. Silva-Jr, Key topics in molecular docking for drug design, Int. J. Mol. Sci. 20 (2019) 4574.

DOI: 10.3390/ijms20184574